Financial Ratios Neurotech International Limited
Equities
NTI
AU000000NTI9
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0140 AUD | 0.00% |
|
-6.67% | - |
| Dec. 16 | Neurotech International receives A$4 million placement commitments | RE |
| Dec. 14 | Neurotech International requests trading halt pending capital raising announcement | RE |
| Fiscal Period: June | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -182.56 | -59.78 | -133.86 | -37.29 | -86.84 | |||||
Return on Total Capital | -284.04 | -79.41 | -182.02 | -41.2 | -90.35 | |||||
Return On Equity % | -462.22 | -127.08 | -289.02 | -63.92 | -142.71 | |||||
Return on Common Equity | -462.22 | -127.08 | -289.02 | -63.92 | -142.71 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 109.02 | 94.4 | 100 | 99.75 | 100 | |||||
SG&A Margin | 1.03K | 221.45 | 215.91 | 110.37 | 146.9 | |||||
EBITDA Margin % | - | -553.11 | -657.16 | -164.5 | -439.2 | |||||
EBITA Margin % | -3.29K | -553.2 | -657.31 | -164.52 | -439.21 | |||||
EBIT Margin % | -3.29K | -553.2 | -657.31 | -164.52 | -439.21 | |||||
Income From Continuing Operations Margin % | -3.29K | -553.35 | -652.32 | -159.54 | -433.6 | |||||
Net Income Margin % | -3.29K | -553.35 | -652.32 | -159.54 | -433.6 | |||||
Net Avail. For Common Margin % | -3.29K | -553.35 | -652.32 | -159.54 | -433.6 | |||||
Normalized Net Income Margin | -2.06K | -345.84 | -407.7 | -99.72 | -271 | |||||
Levered Free Cash Flow Margin | -38.49 | -283.7 | -287.34 | -76.24 | -195.56 | |||||
Unlevered Free Cash Flow Margin | -38.01 | -283.56 | -287.34 | -76.24 | -195.56 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.09 | 0.17 | 0.33 | 0.36 | 0.32 | |||||
Fixed Assets Turnover | - | - | 684.91 | 5.48K | - | |||||
Receivables Turnover (Average Receivables) | 2.72 | - | - | - | - | |||||
Inventory Turnover (Average Inventory) | - | - | - | - | - | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 14.33 | 3.41 | 3.94 | 38.81 | 11.34 | |||||
Quick Ratio | 14.22 | 3.36 | 3.92 | 37.95 | 10.92 | |||||
Operating Cash Flow to Current Liabilities | -6.63 | -4.98 | -4.69 | -14.6 | -31.58 | |||||
Days Sales Outstanding (Average Receivables) | 134.14 | - | - | - | - | |||||
Days Outstanding Inventory (Average Inventory) | - | - | - | - | - | |||||
Average Days Payable Outstanding | -8.87K | - | - | - | - | |||||
Cash Conversion Cycle (Average Days) | - | - | - | - | - | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | - | - | - | - | - | |||||
Total Debt / Total Capital | - | - | - | - | - | |||||
LT Debt/Equity | - | - | - | - | - | |||||
Long-Term Debt / Total Capital | - | - | - | - | - | |||||
Total Liabilities / Total Assets | 22.86 | 29.31 | 25.37 | 2.58 | 8.82 | |||||
EBIT / Interest Expense | -4.35K | -2.46K | - | - | - | |||||
EBITDA / Interest Expense | - | -2.45K | - | - | - | |||||
(EBITDA - Capex) / Interest Expense | - | -2.46K | - | - | - | |||||
Total Debt / EBITDA | - | - | - | - | - | |||||
Net Debt / EBITDA | - | 0.56 | 0.64 | 2.22 | 0.28 | |||||
Total Debt / (EBITDA - Capex) | - | - | - | - | - | |||||
Net Debt / (EBITDA - Capex) | - | 0.56 | 0.64 | 2.22 | 0.28 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 180.72 | 194.44 | 96.59 | 166 | -23.07 | |||||
Gross Profit, 1 Yr. Growth % | 866.23 | 153 | 108.26 | 165.34 | -22.88 | |||||
EBITDA, 1 Yr. Growth % | - | - | 133.57 | -33.41 | 105.4 | |||||
EBITA, 1 Yr. Growth % | 475.22 | -54.87 | 133.58 | -33.42 | 105.38 | |||||
EBIT, 1 Yr. Growth % | 475.22 | -54.87 | 133.58 | -33.42 | 105.38 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 333.67 | -54.75 | 131.75 | -34.94 | 109.08 | |||||
Net Income, 1 Yr. Growth % | 333.67 | -54.75 | 131.75 | -34.94 | 109.08 | |||||
Normalized Net Income, 1 Yr. Growth % | 333.67 | -54.75 | 131.75 | -34.94 | 109.08 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 36.07 | -68.04 | 102.32 | -43.02 | 82.73 | |||||
Accounts Receivable, 1 Yr. Growth % | 1.55K | - | - | - | - | |||||
Inventory, 1 Yr. Growth % | - | - | 8.04 | - | - | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | - | - | -66.68 | -66.86 | - | |||||
Total Assets, 1 Yr. Growth % | 6.1K | -59.59 | 162.43 | 130.06 | -73.47 | |||||
Tangible Book Value, 1 Yr. Growth % | -697.48 | -62.97 | 177.06 | 200.32 | -75.17 | |||||
Common Equity, 1 Yr. Growth % | -697.48 | -62.97 | 177.06 | 200.32 | -75.17 | |||||
Cash From Operations, 1 Yr. Growth % | 239.25 | 27.57 | 113.76 | -27.25 | 96.38 | |||||
Capital Expenditures, 1 Yr. Growth % | - | - | - | - | - | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -71.85 | 1.65K | 99.11 | -29.42 | 97.34 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 96.8 | 1.66K | 99.21 | -29.42 | 97.34 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | -4.22 | 175.01 | 140.59 | 128.67 | 43.05 | |||||
Gross Profit, 2 Yr. CAGR % | 9.87 | 374.76 | 129.54 | 135.07 | 43.05 | |||||
EBITDA, 2 Yr. CAGR % | - | 61.44 | - | 24.71 | 16.95 | |||||
EBITA, 2 Yr. CAGR % | 63.01 | 61.33 | 2.67 | 24.71 | 16.93 | |||||
EBIT, 2 Yr. CAGR % | 63.01 | 61.33 | 2.67 | 24.71 | 16.93 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 24.39 | 40.08 | 2.4 | 22.79 | 16.63 | |||||
Net Income, 2 Yr. CAGR % | 24.39 | 40.08 | 2.4 | 22.79 | 16.63 | |||||
Normalized Net Income, 2 Yr. CAGR % | 63.2 | 40.08 | 2.4 | 22.79 | 16.63 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -39.04 | -34.05 | -19.58 | 7.37 | 2.42 | |||||
Accounts Receivable, 2 Yr. CAGR % | 796.62 | - | - | - | - | |||||
Inventory, 2 Yr. CAGR % | - | - | - | - | - | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | - | - | - | -66.77 | - | |||||
Total Assets, 2 Yr. CAGR % | 176.93 | 400.35 | 2.98 | 145.71 | -21.87 | |||||
Tangible Book Value, 2 Yr. CAGR % | 260.33 | 48.75 | 1.29 | 188.46 | -13.64 | |||||
Common Equity, 2 Yr. CAGR % | 260.33 | 48.75 | 1.29 | 188.46 | -13.64 | |||||
Cash From Operations, 2 Yr. CAGR % | -4.56 | 108.03 | 65.13 | 24.7 | 19.52 | |||||
Capital Expenditures, 2 Yr. CAGR % | - | - | - | - | - | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -76.4 | 136.44 | 489.45 | 18.54 | 18.02 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -76.54 | 528.88 | 492.66 | 18.57 | 18.02 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 95.8 | 35.21 | 145.89 | 148.78 | 59.04 | |||||
Gross Profit, 3 Yr. CAGR % | 62.79 | 41.22 | 260.73 | 140.9 | 62.13 | |||||
EBITDA, 3 Yr. CAGR % | - | 6.35 | 82.59 | - | 47.28 | |||||
EBITA, 3 Yr. CAGR % | 25.65 | 6.33 | 82.51 | -11.13 | 47.27 | |||||
EBIT, 3 Yr. CAGR % | 25.6 | 6.33 | 82.51 | -11.13 | 47.27 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 23.03 | -11.2 | 65.68 | -11.97 | 46.63 | |||||
Net Income, 3 Yr. CAGR % | 23.03 | -11.2 | 65.68 | -11.97 | 46.63 | |||||
Normalized Net Income, 3 Yr. CAGR % | 24.48 | 6.42 | 65.68 | -11.97 | 46.63 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -27.33 | -50.84 | -4.17 | -28.31 | 28.51 | |||||
Accounts Receivable, 3 Yr. CAGR % | 90.3 | - | - | - | - | |||||
Total Assets, 3 Yr. CAGR % | 2.81 | 45.8 | 303.51 | 34.62 | 17 | |||||
Tangible Book Value, 3 Yr. CAGR % | 14.23 | 68.78 | 83.02 | 45.52 | 27.37 | |||||
Common Equity, 3 Yr. CAGR % | -3 | 68.78 | 83.02 | 45.52 | 27.37 | |||||
Cash From Operations, 3 Yr. CAGR % | -8.52 | 5.13 | 109.93 | 25.65 | 45.08 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -67.19 | 3.41 | 123.27 | 190.52 | 40.49 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -67.27 | 3.42 | 328.69 | 191.58 | 40.52 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 1.19 | 47.07 | 108.87 | 66.83 | 97.99 | |||||
Gross Profit, 5 Yr. CAGR % | 7.14 | 27.57 | 83.77 | 73.15 | 149.18 | |||||
EBITDA, 5 Yr. CAGR % | - | -2.25 | 16.72 | 13.35 | 52.79 | |||||
EBITA, 5 Yr. CAGR % | 25.39 | -2.87 | 15.96 | 13.33 | 52.74 | |||||
EBIT, 5 Yr. CAGR % | 25.37 | -2.89 | 15.93 | 13.33 | 52.74 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 21.62 | -3.57 | 14.32 | 1.09 | 43.97 | |||||
Net Income, 5 Yr. CAGR % | 21.62 | -3.57 | 14.32 | 1.09 | 43.97 | |||||
Normalized Net Income, 5 Yr. CAGR % | 24.58 | -2.97 | 15.13 | 12.69 | 43.97 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -28.5 | -38.28 | -24.33 | -32.81 | -1.59 | |||||
Accounts Receivable, 5 Yr. CAGR % | 56.81 | - | - | - | - | |||||
Inventory, 5 Yr. CAGR % | - | -38.33 | -35.73 | - | - | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | -64.5 | -70.25 | - | - | |||||
Total Assets, 5 Yr. CAGR % | 11.35 | -16.39 | 2.88 | 79.65 | 109.23 | |||||
Tangible Book Value, 5 Yr. CAGR % | 48.23 | -12.92 | 8.87 | 109.14 | 35.52 | |||||
Common Equity, 5 Yr. CAGR % | 21.28 | -19.75 | -1.31 | 109.14 | 35.52 | |||||
Cash From Operations, 5 Yr. CAGR % | 5.8 | -1.09 | 15.86 | 12.56 | 67.58 | |||||
Capital Expenditures, 5 Yr. CAGR % | - | -41.55 | - | - | - | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | - | -9.54 | 6.91 | 9.22 | 73.01 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | -9.38 | 7.02 | 9.24 | 155.9 |
- Stock Market
- Equities
- NTI Stock
- Financials Neurotech International Limited
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















